Trials / Active Not Recruiting
Active Not RecruitingNCT07313761
A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations
A Phase 1, Open-label, Randomized, Parallel Group Study to Assess the Relative Bioavailability of Maridebart Cafraglutide (AMG 133) as Two Subcutaneous Presentations in Participants Living With Overweight or Obesity
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 349 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of this trial is to evaluate the pharmacokinetics (PK) of maridebart cafraglutide administered as a single dose using two different SC presentations in participants living with overweight or obesity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Maridebart Cafraglutide | Maridebart cafraglutide will be administered SC. |
Timeline
- Start date
- 2025-12-15
- Primary completion
- 2026-06-26
- Completion
- 2026-06-26
- First posted
- 2026-01-02
- Last updated
- 2026-03-19
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07313761. Inclusion in this directory is not an endorsement.